ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rufinamide

Also written as “Rufinamide”, “SYN111” and “Rufinamide (E2080)”.

Its studies are mostly in Lennox Gastaut Syndrome · Epilepsy · Generalized Anxiety Disorder, led by 3 companies.

Drug pageRufinamide: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 7, 20067 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai50 open or runningphase 3since Jun 7, 2006Jun 7, 2006none ahead
Acorda Therapeuticsits history only10 open or runningphase 2since Jan 7, 2008Jan 7, 2008none ahead
Daiichi Sankyoits history only10 open or runningphase 1since Dec 13, 2024Dec 13, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eisai only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 7, 2006First study: phase 3 study in EpilepsyFirst studyNCT00334958 · 356 enrolled · United States
  2. Mar 15, 2007Phase 3 study in EpilepsyNCT00448539 · 286 enrolled · United States
  3. Jun 14, 20102 phase 3 studies in Lennox Gastaut SyndromeNCT01151540, NCT01146951
  4. Jul 27, 2011Phase 3 study in Lennox Gastaut SyndromeNCT01405053 · 37 enrolled · United States, Canada, France and more

TargetBeta

“Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
QuinidineruleOtsukaphase 317
PhenytoinruleViatrisphase 310

Studies

All 5 Eisai leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01405053Lennox Gastaut Syndrome · United States, Canada, France and more3CompletedNov 2, 201537
NCT01151540Lennox Gastaut Syndrome · Japan3CompletedAug 201354
NCT01146951Lennox Gastaut Syndrome · Japan3CompletedAug 201166
NCT00448539Epilepsy · United States3TerminatedMay 14, 2010286
NCT00334958Epilepsy · United States3CompletedMay 20, 2009356

How it is read

Names in the registry

  • “Rufinamide”, 5 entries
  • “SYN111”, 1 entry
  • “Rufinamide (E2080)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.